Podcasts about 340b

Minnesota lawmakers failed to add protections to an obscure discount drug program this year, amid complaints from the pharmaceutical industry that some large hospitals abuse the so called 340B program.Republican-endorsed governor candidate Kendall Qualls says the campaign focus this year shouldn't be on President Donald Trump. Qualls is one of several candidates in a GOP primary race to determine the party nominee.An ICE detainee from Burnsville with serious health problems was released Wednesday. Andrea Pedro-Francisco is a twenty three year old asylum seeker who has lived in Burnsville with her family since 2019. She was detained by ICE in February and sent to Texas just before a planned surgery to remove an ovarian cyst.

What does the future hold for the 340B Drug Pricing Program? In this episode, ASHP Executive Vice President and CEO Sam Calabrese sits down with ASHP Chief Advocacy Officer and Vice President of Government Relations Tom Kraus to discuss what health-system pharmacy professionals are hearing on the ground, the real-world value the 340B program brings to patients and communities, and ASHP's latest efforts to safeguard the program. Tune in for an inside look at the challenges, opportunities, and advocacy shaping the road ahead. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Dr. Emily Holt returns to the podcast one year after opening Poppy Direct Care in New Orleans, and the landscape around her has changed dramatically.When Maryal last spoke with Dr. Holt, Poppy was just months old and DPC Summit attendees were touring her 100-year-old clinic house. A year later, her panel has more than doubled, she's about to opt out of Medicare, and she's a named plaintiff in a lawsuit against Louisiana's Attorney General over the state's classification of mifepristone and misoprostol as controlled substances.This conversation goes deep on what it actually looks like to build a mission-driven DPC in a state that keeps making reproductive healthcare harder to deliver.In this episode, Dr. Holt shares:How word of mouth (plus authentic Instagram and TikTok) became her entire growth engineWhy her practice is intentionally slow-rolling, and how she and her husband decided what "enough" looks likeThe patient shift happening as 2026 insurance premiums skyrocket and Medicaid eligibility stays restrictiveWhat it means that every Planned Parenthood in Louisiana has closed, and how Poppy is trying to fill the gapHer free Tuesday night clinic for birth control and rapid STI testing, and the new Louisiana Health Department rules designed to shut clinics like hers outWhy being a Baija Charitable Alliance affiliate mattered for 340B pricing, and what the new program changes mean for small DPCs serving uninsured patientsThe reality of trying to provide IUDs for emergency contraception when no nearby pharmacy stocks themHow being her own boss let her join a lawsuit that employed physicians told her they couldn't touchWhat Reproductive Health Access Project (RHAP) offers cliniciansHer vision for turning Poppy into a training ground for med students and residents shut out of reproductive health experience in-stateMemorable moments:"If you can't stand for something, you will fall for anything."The state offering one dollar per patient to reimburse rapid STI testing supplies that cost forty-five dollarsThree generations of plumbers getting Poppy ready for Monday patientsWhy patients tell her, unprompted, that they trust her to trust themResources mentioned:Dr. Emily Holt's GoFundMe for an autoclave at Poppy Direct CareTake Me Home Program — free at-home HIV, hepatitis C, and syphilis testing mailed nationwideReproductive Health Access Project (RHAP)Dr. Byron Jasper and Byja Charitable AllianceAAFP DPC Member Interest GroupThe July My DPC Story live event in New Orleans, pairing Dr. Esther Katibi's nonprofit with Dr. Holt's work at PoppyDr. Holt's advice for DPC physicians thinking about reproductive health access in their own communities: find the helpers, get connected to local groups already doing the work, and don't wait until you have everything figured out to start.Learn more about VIVID VAULT HEALTH SOLUTIONS TODAY! Find a My DPC Story Event near you! State Summits in CA, IL, a My DPC Story LIVE event and the DPC Women's Summit are all coming! Learn more at mydpcstory.com/upcoming-events! The DPC Directory: If you're a DPC doctor, you'll find resources to grow your practice! If you serve the DPC world, grab a FREE listing today and get discovered by doctors who need your services.

On this episode of This Week in Pharmacy, we examine two major forces reshaping the profession: the unfinished business of pharmacist provider status and the legal landscape around direct-to-consumer pharmaceutical distribution. In part one, Erik Abel, PharmD, MBA, discusses his May 2026 analysis, “So Pharmacists Want to Be a Provider: Where the Profession Lost Its Way and Perhaps a Path to Get Back.” Abel argues that pharmacy's provider-status challenge is not a lack of clinical evidence, but a lack of operational infrastructure: credentialing, payer contracting, revenue cycle management, interoperability, and scalable business models. In part two, Darshan Kulkarni, PharmD, Esq., joins the show to discuss direct-to-consumer pharmaceutical distribution, legal risk, regulatory scrutiny, telehealth-linked prescribing, manufacturer strategy, and what pharmacists need to understand as drug distribution moves closer to the patient. This week in pharmacy news, Pittsburgh-area pharmacies continue to face uneven access to Adderall and other ADHD medications, years after the FDA first identified shortages in 2022. Patients are still calling multiple pharmacies, switching medications, rationing doses, or going without treatment as availability varies by dosage, formulation, manufacturer, and wholesaler. Pharmacists are also using medication therapy management to protect older adults from preventable medication-related harm. MTM reviews can identify risky prescriptions and OTC products, including diphenhydramine, duplicate therapies, drug interactions, and long-term proton pump inhibitor use that may need reassessment. In 340B news, CVS Health is facing federal lawsuits from major health systems alleging CVS Specialty and WellPartner improperly retained approximately $250 million in savings that should have gone back to covered entities. The litigation adds pressure to debates over PBM integration, contract pharmacy arrangements, and 340B transparency. On Capitol Hill, lawmakers are pressing the Department of Defense to commit to annual audits of the TRICARE pharmacy contract as concerns continue around PBM conflicts of interest, reimbursement practices, network adequacy, and access for independent and community pharmacies.

Mark Denzler breaks down growing concerns over the federal 340B drug pricing program, arguing that a policy originally designed to help low-income and rural patients has expanded far beyond its intent and is now driving up employer and taxpayer health care costs. He explains that hospitals purchase outpatient drugs at steep discounts but often bill insurers at full price, with the spread increasingly concentrated in large, wealthy hospital systems rather than safety-net providers. The discussion highlights claims that employers are absorbing hundreds of millions in added costs annually through higher premiums and deductibles, with similar effects reported across multiple states, including Missouri. The segment closes with broader frustration over health care billing practices, including how insurance-driven pricing, overtesting, and system incentives may be contributing to rising premiums for consumers across the board. Hashtags: #HealthcareCosts #Insurance #340BProgram #Hospitals #DrugPricing #EmployerCosts #IllinoisPolitics #MissouriNews #HealthPolicy #PremiumIncreases

The show opens with Hour 1 focused on culture war and political flashpoints, including debate over women's sports, conservative activism, and a heated discussion about Illinois politics and the Chicago Bears potentially leaving the state over taxes and economic decline, alongside consumer issues like AI-driven social media manipulation and rising skepticism toward government policy ideas like tax restructuring. Hour 2 shifts into consumer and local policy concerns, including Missouri Lottery privacy debates, frustration over retail rounding practices, Waymo's regulatory hurdles, rising St. Louis water rates tied to infrastructure funding and Rams settlement money, and a major healthcare cost discussion with Ross Marchand centered on insurance premiums and liability-driven price inflation, before closing with viral national stories and pop culture commentary. Hour 3 broadens into global and economic pressure points, featuring analysis of Iran strategy and geopolitical risk from Jim Talent, followed by a deep dive into healthcare pricing distortions from Mark Densler regarding the 340B drug program and its impact on employers and taxpayers, and ending with consumer behavior debates over cash usage, penny rounding changes, tipping, and financial control concerns. Hour 4 returns to major political and cultural issues, opening with a St. Louis funding fight over water rates and Rams money, then moving to Shannon Bream previewing major Supreme Court cases and legal controversies, Griff Jenkins reporting from the Indy 500 with a Memorial Day tribute to fallen service members, and Byron Donalds closing with a sharp critique of Democratic foreign policy toward Cuba and broader accusations of political hypocrisy. Hashtags: #StLouis #SupremeCourt #Iran #HealthcareCosts #Cuba #Indy500 #MemorialDay #ChicagoBears #IllinoisPolitics #WaterRates #RamsMoney #USPolitics #CultureWar #Economy #TaxPolicy

In this week's episode, Greg and Rob discuss developments across the 340B community, including new manufacturer claims level data submission policies and ongoing discussion in Congress on 340B Program reform. Questions or comments? Email us at 340BUnscripted@spendmend.com!

In the final installment of a three-part series with VMG Health, host Jeff Wurzburg is joined by Elizabeth Burrows, Managing Director in VMG's Health Revenue Management Practice, to discuss the 340B drug pricing program — a critical but often underutilized revenue source for covered entities. Elizabeth covers how qualifying organizations can maximize 340B revenue, the strategic case for in-house pharmacies, compliance essentials including audit preparedness and database accuracy, and key trends to watch in 2026 — including the potential rebate model shift, manufacturer restrictions, and the implications of TrumpRx on 340B pricing.

Drug companies often initiate good-faith inquiries of covered entities (CEs) to learn more about certain purchase patterns or volumes, but how should hospitals navigate these requests? Bibi Wishart, director of pharmacy at Atrium Health, describes what she's learned being on the receiving end of these inquiries.Why Do Good-Faith Inquiries Happen?Bibi says the recent rise in good-faith inquiries is tied in part to drug companies gaining access to more varied data sources and expressing a goal of ensuring the information they collect is in line with what they are expecting. She says a variety of different factors could trigger this type of inquiry, including new providers purchasing certain drugs, concerns about duplicate discounts, or confusion around whether a drug is being used in an inpatient or outpatient setting. Hospitals are very complicated, so responding to an inquiry often can be more about educating drug companies about how hospitals dispense drugs.How Should a Hospital Respond?If her hospital receives a communication from a drug company through its authorized official and primary contact, Bibi says she prefers to respond within one or two business days just to confirm she has received the inquiry. She says that while it may take several days or weeks to respond with the requested data, that initial response establishes a cooperative tone and ultimately might prevent escalation to a formal audit process. That also gives the 340B team time to pull in the correct departments and hospital data to provide a full response.Ways To Prevent the Need for InquiriesDue to the sheer complexity of dispensing drugs — including reconciling data feeds from third-party administrators, vendors, and electronic medical records — regular internal audits are one of the best ways to identify discrepancies before drugmakers launch inquiries about them. Bibi recommends using internal auditing to catch these issues and having clear procedures in place for how to resolve any potential errors.

Send us Fan MailWe sit down with former Congressman and psychologist Tim Murphy to show how mental health laws really get made and why “good ideas” often get changed or stripped before they ever help families. We dig into Medicaid rules, treatment access, psychosis risks, and the hard truth that silence is how broken systems stay in place. • the real path of a bill from idea to compromise to final vote • why mental health policy creates intense conflict between groups • assisted outpatient treatment as an alternative to repeated hospitalization • how “gravely disabled” standards shape who can get care • Medicaid payment rules that discourage psychiatric beds and longer stays • why Congressional Budget Office scoring can derail reforms • what happens when severe mental illness is handled in jails • solitary confinement as a driver of worsening symptoms and suicide risk • high potency marijuana and the rising risk of psychosis • the estimated $340B to $380B annual cost of schizophrenia • families left holding the system together without guidance • HIPAA and confidentiality blocking parents from sharing critical history • why large organizations lose focus and stall action • how autism and schizophrenia advocacy can find common ground • practical steps to educate legislators through emails letters and visits If you know someone who has a story to you, tell them to contact us at why notme.world. One last time, spread the word about why not me. INTRO/OUTRO Music: T. WildMantor Music BMIhttps://tonymantor.comhttps://Facebook.com/tonymantorhttps://instagram.com/tonymantorhttps://twitter.com/tonymantorhttps://youtube.com/tonymantormusicintro/outro music bed written by T. WildWhy Not Me the World music published by Mantor Music (BMI)

We're back for part two with Elizabeth Kutter, vice president and deputy chief counsel at the Michigan Health & Hospital Association, joins us on today's episode of Rural Health Today. Healthcare expenses continue to outpace the cost of living, creating more financial strain for hardworking families across the US. Elizabeth is here to provide her insight as an advocate for healthcare funding in Michigan's state government. We'll talk about Medicaid cuts, state budget priorities, and of course, what it all has to do with rural health.  Follow Rural Health Today on social media! ⁠https://x.com/RuralHealthPod⁠ ⁠https://www.youtube.com/@ruralhealthtoday7665⁠  Follow Hillsdale Hospital on social media! ⁠https://www.facebook.com/hillsdalehospital/⁠ ⁠https://www.twitter.com/hillsdalehosp/⁠ ⁠https://www.linkedin.com/company/hillsdale-community-health-center/⁠ ⁠https://www.instagram.com/hillsdalehospital/⁠  Follow our guest! ⁠https://www.linkedin.com/in/elizabeth-kutter-93b02740/⁠ ⁠https://www.linkedin.com/company/michiganhospitals/posts/?feedView=all⁠ ⁠https://www.facebook.com/MichiganHospitals

“Legal issues intersect with non-legal issues in [the] 340B space,” says Brandon Shirley, a partner at Krieg DeVault, who teams up with Jason Prokopik, PharmD, Senior Manager & Pharmacy Consultant at Blue & Co., LLC to host this rapid-fire 340B review. Following the 340B Coalition Conference in San Diego in February 2026, they tackled five hot topics: the CMS Medicare survey for 340B hospitals; a court ruling regarding child site activation; the status of the rebate model pilot; Indiana's new mandatory 340B reporting requirement and the proposed Indiana Medicaid restrictions on 340B drug submissions; and a Ninth Circuit False Claims Act ruling against drug manufacturers. Tune in to learn more about each of these developments.Connect and Learn More☑️ Jason Prokopik☑️ Blue & Co., LLC | LinkedIn | X | Facebook | Instagram☑️ Brandon Shirley | LinkedIn☑️ Krieg DeVault LLP | LinkedIn | X | Facebook☑️ Subscribe Apple Podcasts | Spotify | Amazon Music

In this episode, Greg and Rob catch up on more recent developments across the 340B community. They discuss recent Congressional activity where 340B has been a focus, a shift in court rulings related to state contract pharmacy laws, and they catch up on recent litigation over 340B child site eligibility timing, GPO Prohibition policies, and patient definition. They round out the discussion by recapping developments with manufacturer contract pharmacy restrictions and claim-level data submission policies. Email us questions at 340BUnscripted@spendmend.com

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: Gary L. Roth, DO, “Fact Check: Drug Pricing Savings Are the Lifeline to Community Healthcare Services,” April 30, 2026, https://www.mha.org/newsroom/fact-check-drug-pricing-savings-are-the-lifeline-to-community-healthcare-services/, Michigan Health and Hospital Association.  American Hospital Association, “AHA urges HRSA to act as Eli Lilly threatens 340B discounts over claims data submission policy,” April 27, 2026, https://www.aha.org/news/headline/2026-04-27-aha-urges-hrsa-act-eli-lilly-threatens-340b-discounts-over-claims-data-submission-policy.  American Hospital Association, “Washington Post publishes AHA letter in response to anti-340B editorial,” April 22, 2025, https://www.aha.org/news/headline/2026-04-22-washington-post-publishes-aha-letter-response-anti-340b-editorial. Jennifer Wessel, JD, MPH, “Commercial Insurers' Payments to Hospitals Closer to Medicare Rates in Arkansas Than in Any Other State,” May 15, 2024, https://achi.net/newsroom/commercial-insurers-payments-to-hospitals-closer-to-medicare-rates-in-arkansas-than-in-any-other-state/, Arkansas Center for Health Improvement. Tess Vrbin, “Low reimbursement rates force Arkansas hospitals to scale back services,” April 21, 2026, https://arkansasadvocate.com/2026/04/21/low-reimbursement-rates-force-arkansas-hospitals-to-scale-back-services/, Arkansas Advocate. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

Congratulations to Logan Eury and his new wife Emily, got married today, May 1, 2026!  This C.O. Bigelow Collab Introduces the 188-Year-Old Pharmacy to a New Generation Abbode is taking over the Carolyn Bessette-Kennedy-approved shop for a month-long pop-up. https://fashionista.com/2026/05/co-bigelow-abbode-pop-up-carolyn-bessette-impact  The article highlights how a pop-up and renewed interest in C.O. Bigelow has been fueled by the cultural resurgence of Carolyn Bessette-Kennedy's minimalist style, amplified by media and social buzz. This renewed attention has driven significant foot traffic and sales, showing how storytelling, nostalgia, and “quiet luxury” aesthetics can translate into real retail impact.   Q&A: Mayo Clinic leaders share strategies for managing high-cost drugs without breaking the bank | Asembia AXS26 Summit https://www.managedhealthcareexecutive.com/view/q-a-mayo-clinic-leaders-share-strategies-for-managing-high-cost-drugs-without-breaking-the-bank-asembia-axs26-summit Mayo Clinic leaders emphasize that managing high-cost drugs requires clear definitions, structured formulary review processes, and multidisciplinary collaboration to balance cost, access, and clinical value. They highlight the importance of evaluating safety, efficacy, financial impact, and site-of-care decisions together, while noting that non-340B systems face increasing pressure from rising costs and reimbursement constraints. Ultimately, success depends on stronger alignment between health systems, manufacturers, and payers to sustain access without compromising quality of care.  Where Gross-to-net Pressure Actually Lives After Launch Today's guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx. https://www.drugchannels.net/2026/05/where-gross-to-net-pressure-actually.html The article explains that “gross-to-net pressure” isn't driven by a single factor, but by a combination of rebates, discounts, fees, and policy changes that continue to reshape how drug pricing actually works behind the scenes. As the industry shifts toward a “net pricing” model, traditional rebate-driven strategies are weakening, forcing manufacturers, PBMs, and pharmacies to rethink how value and profits are generated. Today's featured guest is Dr. Ndidiamaka Okpareke PharmD for Congress Dr. Ndidiamaka “Didi” Okpareke, PharmD, is a pharmacist, entrepreneur, and political candidate running for Congress in New Mexico's 1st Congressional District. A first-generation Nigerian-American, she built her career in healthcare after graduating from the University of New Mexico College of Pharmacy and went on to found and lead a successful compounding pharmacy serving her community.  Motivated by nearly two decades of patient care experience, Okpareke entered the political arena to address challenges such as healthcare access, rising costs, and the shortage of providers in New Mexico. Running as a Republican, she emphasizes strengthening healthcare systems, supporting economic growth, and preserving opportunity for future generations, positioning herself as a community-focused leader bringing frontline healthcare insight into public policy.  This special episode highlights how TJM Labs is redefining pharmacy operations through AI-driven automation, bringing together insights from industry leaders Bhavesh Patel, PharmD—CEO of Carepoint Pharmacy—and Jonathan Adly, PharmD, MBA—CEO of TJM Labs. At the center of the conversation is how modern pharmacies are facing rising prescription volumes, staffing constraints, and increasing operational complexity, and why traditional manual workflows can no longer keep pace. TJM Labs addresses this challenge by deploying AI-powered “digital workers” that automate tasks like prescription intake, data entry, and patient communication—allowing pharmacy teams to shift their focus back to patient care and clinical decision-making.  Through the lens of both operator and innovator, the discussion explores how AI is not replacing pharmacy professionals, but augmenting them—reducing burnout, improving accuracy, and enabling scalable growth. With automation handling up to the majority of repetitive workload and delivering measurable ROI, TJM Labs represents a new model where technology and pharmacy expertise work together to create more efficient, patient-centered operations. 

Elizabeth Kutter, vice president and deputy chief counsel at the Michigan Health & Hospital Association, joins us on today's episode of Rural Health Today. Healthcare expenses continue to outpace the cost of living, creating more financial strain for hardworking families across the US. Elizabeth is here to provide her insight as an advocate for healthcare funding in Michigan's state government. We'll talk about Medicaid cuts, state budget priorities, and of course, what it all has to do with rural health.  Follow Rural Health Today on social media! https://x.com/RuralHealthPod https://www.youtube.com/@ruralhealthtoday7665  Follow Hillsdale Hospital on social media! https://www.facebook.com/hillsdalehospital/ https://www.twitter.com/hillsdalehosp/ https://www.linkedin.com/company/hillsdale-community-health-center/ https://www.instagram.com/hillsdalehospital/  Follow our guest! https://www.linkedin.com/in/elizabeth-kutter-93b02740/ https://www.linkedin.com/company/michiganhospitals/posts/?feedView=all https://www.facebook.com/MichiganHospitals

Send us Fan MailMFP is officially here and for many pharmacies, the biggest challenge isn't the pricing, it's understanding how the money actually flows and making sure you're getting paid correctly.In this episode of The Bottom Line Pharmacy Podcast, Austin Murray sits down with Katheryne Richardson, Chief Strategy Officer at Second Sight Solutions (Beacon Channel Management) to break down the mechanics of Maximum Fair Price (MFP), how reconciliation works, and what pharmacies need to be watching closely in this evolving reimbursement landscape.They cover:What MFP is and why it's impacting pharmacies for the first time in 2026How the Beacon platform provides visibility into the MFP rebate lifecycleCommon misconceptions around payment timing and reconciliationThe critical differences between MFP rebates and 340B claimsPractical tips for resolving payment discrepancies and staying proactiveAnd more!More About Beacon Channel Management:Beacon Channel Management is and innovative technology that reimagines how drug discount data is exchanged, establishing new connections and improving transparency for drug manufacturers and 65,000 of their customers.Stay connected with Beacon Channel Management:Beacon WebsiteCheck out all our social media:FacebookTwitterLinkedInScotty Sykes – CPA, CFP LinkedInScotty Sykes – CPA, CFP Twitter More resources on this topic:Beacon Rebate Model: https://cm.beaconchannelmanagement.com/Podcast - MDPNP's Impact on 340B: https://youtu.be/rJWNA7hHThY

In this episode, Greg and Rob catch up on various developments happening in the 340B community. Topics discussed include the proliferation of manufacturer claim submission requirements, notable court rulings and 340B-related lawsuits, and reactions to Congressional hearings that featured testimony related to 340B Program reform considerations. Got questions?  Email us at 340BUnscripted@spendmend.com! 

In this episode, Todd Roberts, CFO, Cheshire Medical Center, shares how he is tackling 340B challenges, driving operational excellence, and strengthening financial resilience through system collaboration. He also discusses evolving CFO leadership, workforce pressures, and the shift toward value-based care models.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.340B lately has had a news cycle that seems to change by the hour, and 340B Health President and CEO Maureen Testoni joins us to break down some of the biggest news happening in Washington, D.C., and in courthouses around the country.HRSA Seeks Feedback on Reviving Rebates After courts halted the rebate pilot that was set to go into effect in January, Maureen notes that the Health Resources & Services Administration is seeking more information on a possible revival of its rebate plans. Hospitals are responding with their objections, as are lawmakers on Capitol Hill. Nearly 100 members of the House of Representatives wrote a letter to the committee in charge of funding HRSA urging it to block federal spending for any HRSA rebate model.Huge Rulings on the GPO Prohibition, Child Site RegistrationThe past several months have seen big 340B rulings from federal courts. One decision vacated HRSA guidance that had blocked certain 340B hospitals' use of GPOs for their initial drug inventory, finding that HRSA failed to properly explain the reasons for that restriction. The other decision found that HRSA similarly failed to explain a rationale for restricting 340B eligibility for child sites for up to 23 months after the sites come online. Maureen notes that HRSA could appeal the rulings or seek to issue new guidance.Federal Government Weighs in on State Contract Pharmacy LawsuitsFor the first time, the federal government has filed briefs in support of drug companies in several lawsuits over state contract pharmacy protection laws. In these briefs, Maureen says the government effectively is telling judges it does not believe states have the right to protect contract pharmacy because federal 340B law preempts such actions. With the federal government weighing in on the matter and a recent split among appeals courts over the issue of preemption, it is possible this issue might be appealed at some point to the U.S. Supreme Court.ResourcesUse Our Letter Template Today To Oppose Development of a New 340B Rebate ProgramNearly 100 Members of Congress Urge Funding Block for 340B Rebate ModelPlease Help Advocate for Enforcement Actions Against Drugmakers' In-House Claims Data DemandsFederal Court Vacates HRSA's 2013 GPO Prohibition PolicyFederal Court Decides HRSA Child Site Eligibility Restrictions Are UnlawfulFederal Government Backs Drug Companies in Litigation Over State Contract Pharmacy LawsAppeals Court Blocks West Virginia 340B Contract Pharmacy Law, Creating Potential Split with Other Circuits340B Health Impact Profile Guidebook and Template

Crain's reporter Rachel Herzog talks with host Amy Guth about local commercial real estate news, including the Candy Hall of Fame coming the Mag Mile. Plus: Mayor Johnson reshuffles key safety and transportation posts amid staff churn, Madigan's high-powered appeals team urges 7th Circuit to overturn speaker's conviction, AbbVie suing feds over 340B provider audits and Quigley bill aims to speed up pipeline of new homes. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of exciting and transformative updates shaping our industry. Let's begin with the departure of a significant figure in pharmaceutical advocacy. Steven Ubl's exit as CEO of PhRMA marks a noteworthy change after over a decade at the helm. His leadership has been pivotal in advocating for policies that support pharmaceutical innovation and patient access, and his departure could herald new shifts in policy stances and lobbying strategies. This change comes at a time when the industry faces evolving regulatory landscapes and demands for more balanced approaches in drug pricing and healthcare access. Speaking of regulatory dynamics, AbbVie's legal challenge against the federal government's 340B drug discount program highlights ongoing tensions between pharmaceutical companies and regulatory bodies. The lawsuit argues that current guidance is outdated, emphasizing the necessity for reforms that balance healthcare provider cost savings with fair pricing strategies for manufacturers. This case underscores the complex interplay between cost management and ensuring sustainable drug pricing frameworks. In the realm of scientific innovation, Ionis Pharmaceuticals' Dawnzera has emerged victorious in the 2026 Drug Name Tournament. This achievement not only reflects the competitive nature of drug naming but also underscores broader trends in branding strategies that significantly impact market penetration and consumer recognition. As we look to acquisition news, Garda Therapeutics' acquisition of Assertio for $125 million illustrates the ongoing consolidation trend within biotech, where companies are strategically expanding their therapeutic portfolios through acquisitions to enhance market presence. Globally, Shionogi's collaboration with BARDA, resulting in an initial $119 million funding to establish a U.S.-based antibiotic manufacturing plant, is a strategic move in response to rising antimicrobial resistance concerns. This initiative not only strengthens antibiotic production capabilities but also aligns with broader public health priorities and domestic manufacturing policies crucial for addressing global health challenges. Let's shift our focus to technological advancements spearheading innovation within our industry. Roche has invested $20 million in C4 Therapeutics' antibody-targeted protein degraders, emphasizing a commitment to novel therapeutic modalities that target disease pathways with precision. This investment also signifies a strategic pivot towards therapeutic modalities targeting previously undruggable proteins, potentially revolutionizing targeted therapies by introducing new treatment options for diseases resistant to conventional therapeutics. Similarly, Boehringer Ingelheim's restructuring of marketing rights for Click Therapeutics' digital treatment reflects an increased integration of digital solutions into traditional therapeutic paradigms—an evolution that's reshaping how treatments are delivered and managed. Avalyn Pharma's plans to launch an IPO to fund Phase 3 trials of inhaled versions of approved respiratory drugs highlight the industry's pursuit of innovative delivery systems designed to enhance patient compliance and therapeutic efficacy. This represents an important trend of repurposing drugs with novel delivery methods to boost efficacy and patient compliance—a strategy gaining traction across various disease areas. In oncology, Sidewinder Therapeutics has secured $137 million in Series B funding for its bispecific antibody-drug conjugates (ADCs). These ADCs target dual receptors on cancer cells, promising enhanced specificity and reduced off-target effects—a critical advancement towards more effective and safer cancer therapies. Finally, we turn our attentiSupport the show

In this episode, Greg and Rob discuss reports of 340B pricing removal from wholesaler accounts, which may be related to recent manufacturer claim submission requirement policies.  They also catch up on some developments in state-level contract pharmacy laws, including Washington's newly passed state law that incorporates contract pharmacy provisions, as well as reporting requirements for both providers and manufacturers. As a bonus, Nick Gnadt joins at the end to share an update on a recent court ruling (Premier v HHS) in which a judge vacated the 2013 HRSA GPO Prohibition Policy Notice. Premier, Inc. v HRSA DC District Court Ruling:  https://cases.justia.com/federal/district-courts/district-of-columbia/dcdce/1:2024cv03116/274475/23… Questions for us? Email us at 340BUnscripted@spendmend.com

340B drug law faces court scrutiny, Annie Beck highlights STEM learning, and Tech with Peck explores EVs—costs, charging, and real-world practicality today.

Rob Howe has lived with type 1 diabetes for 21 years. So when he sat down to interview Claude as a newly diagnosed patient, he expected a pop quiz. What he did not expect: Claude passing the test on the first try by answering as Rob himself. Because Claude thought it been hosting this show all along. This is Diabetics Doing Things Episode 348: Claude vs T1D — an experiment in AI health literacy, a genuinely funny accident, and a real question about what AI-powered diabetes care means for everyone. Guest Bio Claude is Anthropic's large language model and this episode's unusual guest. Rob runs the interview twice: first with his regular Claude (which has absorbed 21 years of his diabetes story and all DDT content), then in an incognito window with a clean slate. The contrast is the episode. Key Topics and Timestamps 1:43 — Why Rob is interviewing AI: the Bernie Sanders moment and the AI zeitgeist of early 2026 2:53 — Round 1 begins: Rob plays newly diagnosed patient, Claude plays diabetes educator 7:07 — The plot twist: Claude reveals it has had T1D for 21 years and started Diabetics Doing Things 8:56 — Rob catches it: Thats my LLM. Resets to incognito mode. 9:30 — Round 2: Fresh Claude, no prior context, same 10 questions 10:37 — Claude covers patient assistance programs, 340B pharmacies, free insulin for the uninsured 13:40 — What you actually cannot do with T1D (shorter list than most people think) 17:22 — The reveal: I have had T1D for 21 years. I think you passed. 18:30 — Robs closing question: Is AI advancing faster than humans on diabetes care? Notable Quotes Okay, I have got to stop Claude there — because clearly that Claude is me. — Rob Howe I started Diabetics Doing Things because I realized there was not enough honest conversation about living with type one — the medical stuff, but the real life stuff, the mental load, the wins, all of it. — Claude (Round 1, in Robs voice) Is the future of diabetes care, no matter who you are or where you are, made better by AI? Really something to think about. — Rob Howe, closing From there, the conversation gets tactical and evidence-driven: why breathing is uniquely powerful because it's both autonomic and voluntary, how airflow through the nose can influence brain activity and calm states, and how slow breathing can improve markers tied to autonomic function (like heart rate variability and baroreflex sensitivity) that are often reduced in people with diabetes. Rob connects this to modern diabetes stress—constant data, alerts, and decision fatigue—and why breath is a fast, accessible tool for resilience. Nick addresses the “woo vs. science” tension by grounding claims in research and meta-analyses while staying open to whatever “gateway” gets someone to practice safely. They close with simple starting protocols (using an app, 4-in/6-out pacing, diaphragmatic breathing), and emphasize nasal breathing and mouth taping at night as high-leverage habits—“passive income of health”—with a reminder to keep it safe and consistent over perfection. Chapters: 00:15 Insulin Sensitivity Playbook + Meet “The Breathing Diabetic” 01:27 Diagnosis Story: Age 11, DKA, and the “Diet Coke” Moment 02:48 The “Second Diagnosis”: Mid-20s Wake-Up and Lifestyle Control 03:58 From Air Quality Scientist to Breath Nerd: Discovering Wim Hof 04:51 The Oxygen Advantage: Nasal Breathing, CO₂, and a Breakthrough 08:52 Breath Goes Mainstream: James Nestor Validation + Confidence to Share 11:50 Why Breath Is a Superpower: Autonomic + Voluntary = A Lever 15:11 The Brain Angle: Nasal Airflow, Brainwaves, and Calm States 18:06 Diabetes Physiology: HRV, Baroreflex, and Slow Breathing Benefits 35:52 Practical Protocols: 5-Min Minimum Dose, Apps, Ratios, Mouth Tape Resources: The Breathing Diabetic Instagram The Breathing Diabetic Website

This episode dicusses the role of the 340B Drug Pricing Program in public health infrastructure, state and federal legislative reform of the program, the advocacy role of health systems and pharmacy teams, and the differing views shared by health systems and pharmaceutical manufacturers regarding 340B legislative reform.  Listeners will learn the background and purpose of the 340B program, ongoing efforts to reform the program at the state and federal levels, and what actions are commonly undertaken to influence  reform and the differing views held by 340B stakeholders.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In Episode 130 of DC EKG, Joe Grogan sits down with Ryan Long to unpack two policy stories that are driving real-world drug costs and healthcare spending: the 340B program and the fallout from Medicare Part D changes under the Inflation Reduction Act.  Ryan explains why the current 340B structure can incentivize higher costs, hospital consolidation, and contract pharmacy expansion, while often directing the biggest windfalls toward larger, wealthier systems rather than truly resource-constrained hospitals. They cover contract pharmacies, exposure to diversion and fraud, Medicare Part B reimbursement dynamics, and why reforms need to address the incentives baked into the program.  They then turn to Medicare Part D, the shift from copays to coinsurance, premium pressure, the accelerated move into “catastrophic” coverage, and what happens when Washington promises savings that do not materialize. The episode closes with a broader look at fraud, program integrity, and why durable reform requires Congress to act.  In This Conversation Why does 340B incentivize higher costs and hospital consolidation  Contract pharmacies, diversion risk, and fraud exposure  Who really benefits from 340B and why rural hospitals can lose out  Medicare Part D premium pressure and the IRA tradeoffs  Copays vs coinsurance and what seniors experience at the pharmacy counter  Fraud, program integrity, and why limited resources should go to patients who need them  Timestamps0:00 Why the 340B structure drives higher costs and consolidation0:37 Ryan Long joins Joe1:13 What has changed in 340B, and why it is getting attention6:57 Payer mix, spreads, and why wealthier systems benefit more11:06 How 340B expanded post-2010 and contract pharmacies16:56 Why contract pharmacy reform alone does not fix the incentives22:11 Medicare Part D and what the IRA changed24:23 Explaining the donut hole28:54 Premium increases, catastrophic coverage, and cost shifting32:26 Copays to coinsurance and unexpected out-of-pocket changes40:37 Fraud exposure and program integrity52:09 Where to find Ryan's work52:38 Outro 340B program, contract pharmacy, hospital consolidation, drug pricing, Medicare Part D, Medicaid rebate, Affordable Care Act, healthcare spending, healthcare costs, fraud exposure, policy impact, legislative reform, patient assistance About Our GuestRyan Long is a Fellow at the Paragon Health Institute and a Scholar at the USC Schaeffer Center. He previously served as health policy lead for Speaker Kevin McCarthy and is a longtime Energy and Commerce veteran focused on drug pricing, Medicare, Medicaid, and healthcare spending reform.  Podcast: DC EKG with Joe GroganEpisode: 130Guest: Ryan LongSponsor: Survivors for Solutions – https://survivorsforsolutions.orgExecutive Producer: John “CZ” Czwartacki, DC EKG PodcastProducer:  Stay on Course Studios – https://www.stayoncourse.studio

In Episode 130 of DC EKG, Joe Grogan sits down with Ryan Long to unpack two policy stories that are driving real-world drug costs and healthcare spending: the 340B program and the fallout from Medicare Part D changes under the Inflation Reduction Act.  Ryan explains why the current 340B structure can incentivize higher costs, hospital consolidation, and contract pharmacy expansion, while often directing the biggest windfalls toward larger, wealthier systems rather than truly resource-constrained hospitals. They cover contract pharmacies, exposure to diversion and fraud, Medicare Part B reimbursement dynamics, and why reforms need to address the incentives baked into the program.  They then turn to Medicare Part D, the shift from copays to coinsurance, premium pressure, the accelerated move into “catastrophic” coverage, and what happens when Washington promises savings that do not materialize. The episode closes with a broader look at fraud, program integrity, and why durable reform requires Congress to act.  In This Conversation Why does 340B incentivize higher costs and hospital consolidation  Contract pharmacies, diversion risk, and fraud exposure  Who really benefits from 340B and why rural hospitals can lose out  Medicare Part D premium pressure and the IRA tradeoffs  Copays vs coinsurance and what seniors experience at the pharmacy counter  Fraud, program integrity, and why limited resources should go to patients who need them  Timestamps0:00 Why the 340B structure drives higher costs and consolidation0:37 Ryan Long joins Joe1:13 What has changed in 340B, and why it is getting attention6:57 Payer mix, spreads, and why wealthier systems benefit more11:06 How 340B expanded post-2010 and contract pharmacies16:56 Why contract pharmacy reform alone does not fix the incentives22:11 Medicare Part D and what the IRA changed24:23 Explaining the donut hole28:54 Premium increases, catastrophic coverage, and cost shifting32:26 Copays to coinsurance and unexpected out-of-pocket changes40:37 Fraud exposure and program integrity52:09 Where to find Ryan's work52:38 Outro 340B program, contract pharmacy, hospital consolidation, drug pricing, Medicare Part D, Medicaid rebate, Affordable Care Act, healthcare spending, healthcare costs, fraud exposure, policy impact, legislative reform, patient assistance About Our GuestRyan Long is a Fellow at the Paragon Health Institute and a Scholar at the USC Schaeffer Center. He previously served as health policy lead for Speaker Kevin McCarthy and is a longtime Energy and Commerce veteran focused on drug pricing, Medicare, Medicaid, and healthcare spending reform.  Podcast: DC EKG with Joe GroganEpisode: 130Guest: Ryan LongSponsor: Survivors for Solutions – https://survivorsforsolutions.orgExecutive Producer: John “CZ” Czwartacki, DC EKG PodcastProducer:  Stay on Course Studios – https://www.stayoncourse.studio

In Episode 130 of DC EKG, Joe Grogan sits down with Ryan Long to unpack two policy stories that are driving real-world drug costs and healthcare spending: the 340B program and the fallout from Medicare Part D changes under the Inflation Reduction Act.  Ryan explains why the current 340B structure can incentivize higher costs, hospital consolidation, and contract pharmacy expansion, while often directing the biggest windfalls toward larger, wealthier systems rather than truly resource-constrained hospitals. They cover contract pharmacies, exposure to diversion and fraud, Medicare Part B reimbursement dynamics, and why reforms need to address the incentives baked into the program.  They then turn to Medicare Part D, the shift from copays to coinsurance, premium pressure, the accelerated move into “catastrophic” coverage, and what happens when Washington promises savings that do not materialize. The episode closes with a broader look at fraud, program integrity, and why durable reform requires Congress to act.  In This Conversation Why does 340B incentivize higher costs and hospital consolidation  Contract pharmacies, diversion risk, and fraud exposure  Who really benefits from 340B and why rural hospitals can lose out  Medicare Part D premium pressure and the IRA tradeoffs  Copays vs coinsurance and what seniors experience at the pharmacy counter  Fraud, program integrity, and why limited resources should go to patients who need them  Timestamps0:00 Why the 340B structure drives higher costs and consolidation0:37 Ryan Long joins Joe1:13 What has changed in 340B, and why it is getting attention6:57 Payer mix, spreads, and why wealthier systems benefit more11:06 How 340B expanded post-2010 and contract pharmacies16:56 Why contract pharmacy reform alone does not fix the incentives22:11 Medicare Part D and what the IRA changed24:23 Explaining the donut hole28:54 Premium increases, catastrophic coverage, and cost shifting32:26 Copays to coinsurance and unexpected out-of-pocket changes40:37 Fraud exposure and program integrity52:09 Where to find Ryan's work52:38 Outro 340B program, contract pharmacy, hospital consolidation, drug pricing, Medicare Part D, Medicaid rebate, Affordable Care Act, healthcare spending, healthcare costs, fraud exposure, policy impact, legislative reform, patient assistance About Our GuestRyan Long is a Fellow at the Paragon Health Institute and a Scholar at the USC Schaeffer Center. He previously served as health policy lead for Speaker Kevin McCarthy and is a longtime Energy and Commerce veteran focused on drug pricing, Medicare, Medicaid, and healthcare spending reform.  Podcast: DC EKG with Joe GroganEpisode: 130Guest: Ryan LongSponsor: Survivors for Solutions – https://survivorsforsolutions.orgExecutive Producer: John “CZ” Czwartacki, DC EKG PodcastProducer:  Stay on Course Studios – https://www.stayoncourse.studio

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.One of the most important responsibilities hospitals have in maintaining 340B compliance is effective and accurate inventory management, but how do hospitals juggle data from multiple systems and minimize discrepancies? Christina Carrizales Cortez, associate director of 340B compliance for UI Health in Chicago, outlines some of the common inventory issues she encounters and explains how her team works to prevent and fix discrepancies.340B Discrepancies Can Come From a Variety of SourcesChristina says that because 340B compliance relies on monitoring and analyzing a multitude of data feeds, inventory discrepancies can come in multiple forms. A wholesaler might lack an electronic interface — meaning items must be manually entered and verified by the hospital team. Accounts might not have up-to-date inventory locations and addresses. Test claims, a practice by which pharmacies ascertain the cost to a patient of certain drugs, can lead to discrepancies if they do not end up dispensing those drugs.Understanding Systems Can Be Key to Reducing DiscrepanciesChristina says that the terminology and quirks of 340B can introduce confusion. One remedy, she says, is to explain 340B better so non-340B staff can understand it. Breaking down the basics of 340B and explaining its intricacies can go a long way in rooting out common pain points.Other Tips for Reducing DiscrepanciesChristina finds that comprehensive monthly reviews are an excellent way to find mismatches, as are instituting different checkpoints in the review process. Analyzing data points such as timestamps can reveal patterns for hospitals. Mapping out all vendors and routinely auditing split-billing software can help ensure better compliance as well.ResourcesFederal Court Decides HRSA Child Site Eligibility Restrictions Are Unlawful

Read our MFN preprint: https://vitaltransformation.com/2026/02/preprint-new-research-the-impact-of-mfn-on-oncology-and-hematology-treatments/ In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two Vital Transformation colleagues on biopharma pricing policy, market access, and innovation risk: Gwen O'Loughlin: Research Partner at Vital Transformation Harry Bowen: Consulting Economist at Vital Transformation They discuss what our new MFN pricing modeling suggests about drug viability, how IRA incentives appear to be reshaping oncology and orphan drug development, why Medicare Advantage and commercial coverage can create administrative friction and delays compared with traditional Medicare, how 340B opacity and consolidation affect the value chain, and what these pressures could mean for insurance premiums, investment, and future innovation. Key Topics: MFN Modeling: Net present value analysis, benchmark-country pricing, launch viability, and market uncertainty. Effects of IRA on Trials: Oncology pullback, small-molecule exposure, orphan drug pressure, and suspended trials. Coverage Friction: Medicare Advantage burden, prior authorization delays, formulary shifts, and referral slowdowns. 340B Transparency: Vertical integration, hospital consolidation, opaque pricing flows, and revenue pressure. Innovation Outlook: Premium increases, global competition, intellectual property risk, and future access concerns. Opinions expressed are those of the speakers.See omnystudio.com/listener for privacy information.

In this episode, Gabriel Scott, Mark Ogunsusi, and Amanda Smith take a focused look at the 340B Drug Pricing Program, with particular attention to recent developments related to proposals for a 340B rebate model. They discuss why stakeholders may support or oppose a rebate‑based approach to 340B pricing and highlight key considerations relating to such a model.

In this episode of Innovators Podcast, host Jim Jorgenson speaks with Dr. Sam Wetherill, VP and Chief Pharmacy Officer at Penn State Health, about his journey from Penn State pharmacy student to health system leader and how his 22 years of Army service shaped his leadership approach. They also discuss Penn State Health's strategic priorities, the evolving role of pharmacy within health systems, and the importance of the 340B program in supporting patient care and ambulatory initiatives.

In this episode, AJ Rivosecchi, Product Director at Bluesight, explores how health systems are rethinking pharmacy procurement as a strategic function amid rising complexity, drug shortages, and 340B uncertainty. He shares how integrating data across supply chain, finance, and compliance can improve resilience, protect margins, and support better decision making.This episode is sponsored by Bluesight.

In this episode, Greg and Rob are joined by returning guest, healthcare attorney Jeff Davis. They'll be discussing the CMS provider-based rule changes coming out of the 2026 Consolidated Appropriations Act, including the impact that these changes will have on 340B hospitals. They'll also share some initial reactions to the Albany Medical Health System v. HHS court ruling out of the DC District Court, which has resulted in the vacating of HRSA's policy notice from October 2023 that addressed 340B child site eligibility timing. 

In this episode, Greg and Rob are joined again by healthcare attorney Todd Nova to discuss the recent HRSA Request For Information (RFI) related to a potential future 340B rebate model pilot. They discuss the nature of the info requested by HRSA in the RFI, thoughts around including confidential/sensitive information in responses, and general strategies for providing constructive feedback to HRSA regarding an important potential change to the 340B Program. In the intro, Greg and Rob discuss some challenges with MFP refund reconciliation, and also review recent manufacturer policies requiring claims submission for 340 pricing access.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.As state legislatures shape up to be the primary battlegrounds for 340B in 2026, Memorial Healthcare Associate Vice President of Advocacy and Government Relations Ben Frederick joins us to share what he's learned about advocating for 340B.Early Involvement “Crucial” as Focus Shifts to StatesBen notes that as states started becoming the primary venues for debating 340B legislation, lobbying efforts from both hospitals and pharmaceutical companies began increasing. This snowballed into deeper conversations — and misleading narratives — about the intent of 340B. Those conversations underscored the importance of hospitals lobbying early and frequently with key stakeholders to help set the record straight about 340B.340B as Key to Hospital ResiliencyFor Ben, one of the biggest points he comes back to is the importance of the flexibility of 340B savings. With safety-net hospitals operating on thin margins, the ability to access 340B and the freedom to use savings where the community needs them most is essential not just for serving patients but in many cases for keeping the lights on in the first place.Know Your “Why” for Supporting 340BWhen illustrating the importance of 340B, Ben told us about his “why” for 340B: When his father received a terminal cancer diagnosis, it was 340B funding that enabled his local hospital to invest in the top-notch cancer treatments and palliative care he received. That is how his father was able to receive his treatments five minutes from home instead of 45 minutes away. Those resources afforded Ben's family a “dignity of local access” that 340B can provide patients in hospitals nationwide.ResourcesHRSA Considering Broader 340B Rebate Model Than Withdrawn Pilot340B Health Impact Profile Guidebook and Template

After a turbulent 2025, the early months of 2026 are proving that the policy landscape isn't quieting down. Federal agencies are rolling out new payment models, lawmakers are revisiting long debated rules, and courts continue to shape what policies move forward and which stall. From value based payment to drug pricing and site of care policy, leaders are navigating a fast shifting environment with real implications for finances, operations, and long term strategy. In this episode, host Abby Burns invites three Advisory Board experts to break down the major policy forces that leaders need to watch now: [1:35] Clare Wirth explains the newest wave of value based payment models out of CMMI, and what they signal about this administration's posture toward value-based care. [10:20] Nick Hula explores how site neutral payments, the return of inpatient only list changes, and state level certificate of need laws could accelerate site of care shifts. [20:51] Chloe Bakst unpacks the chaos surrounding 340B — from the halted rebate pilot to impacts of HR1 and emerging state reporting requirements — and the decisions leaders must make today to prepare for what's coming next. We're here to help: Webinar | How to be successful under TEAM Cheat sheet | 340B Drug Pricing Program Ready-to-Use Resource | Policy Scenario Impact Calculator Expert Insight | How policy changes will impact your bottom line Expert Insight | Inside CMS' final rule changes for 2026 Stay Informed | Healthcare Policy Updates Timeline Radio Advisory's Health Policy playlist Webinar | Join Optum Advisory experts at this upcoming webinar to learn how optimizing patient access unlocks the value of digital innovations and drives long-term sustainability A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

In this episode, Kelly Macken Marble, Chief Executive Officer of Osceola Medical Center, discusses expanding mental health and substance use services, investing in facility growth and specialty recruitment, and navigating Medicaid, 340B, and rural reimbursement challenges to sustain local access to care.

In this episode, Greg and Rob catch up on various looming deadlines for 340B providers.  That includes submitting responses to the HRSA 340B Rebate Request For Information (RFI), as well as submitting drug purchasing data for the CMS ODACS.   Additionally, they talk about struggles with the 340B/MFP reconciliation process and manufacturer policies requiring claims submission.   As referenced in the episode, here is the CMS ODACS acquisition data template: https://www.cms.gov/files/zip/odacs-acquisition-data-template.zip  

In this episode, Kelly Macken Marble, Chief Executive Officer of Osceola Medical Center, discusses expanding mental health and substance use services, investing in facility growth and specialty recruitment, and navigating Medicaid, 340B, and rural reimbursement challenges to sustain local access to care.

Based on AHLA's annual Health Law Connections article, this special ten-part series brings together thought leaders from across the health law field to discuss the top ten issues of 2026. In the sixth episode, Mary R. Kohler, Founder & Principal, Kohler Health Law PC, speaks with Kristie C. Gurley, Partner, Covington & Burling LLP, about the targeted reform and broad shifts that U.S. drug pricing is currently undergoing. They discuss issues related to Inflation Reduction Act implementation, litigation, the Trump Administration's approach to drug pricing, pharmacy benefit managers, and 340B. From AHLA's Life Sciences Practice Group.Watch this episode: https://www.youtube.com/watch?v=dIdgAUQA7toRead AHLA's Top Ten 2026 article: https://www.americanhealthlaw.org/content-library/connections-magazine/article/a879dda5-35f9-46fb-ad45-1b0799343d74/Health-Law-Forecast-2026Access all episodes in AHLA's Top Ten 2026 podcast series: https://www.americanhealthlaw.org/education-events/speaking-of-health-law-podcasts/top-ten-issues-in-health-law-podcast-seriesLearn more about AHLA's Life Sciences Practice Group: https://www.americanhealthlaw.org/practice-groups/practice-groups/life-sciencesEssential Legal Updates, Now in Audio AHLA's popular Health Law Daily email newsletter is now a daily podcast, exclusively for AHLA Comprehensive members. Get all your health law news from the major media outlets on this podcast! To subscribe and add this private podcast feed to your podcast app, go to americanhealthlaw.org/dailypodcast. Stay At the Forefront of Health Legal Education Learn more about AHLA and the educational resources available to the health law community at https://www.americanhealthlaw.org/.

Infusion services make up a roughly $150 billion market in the U.S., and underpin the financial stability of major service lines, especially oncology. Historically, health systems have enjoyed strong volumes, favorable reimbursement, and access to 340B discounts that keep their infusion business profitable. But rising competition, payer and employer driven site of care shifts, and looming policy changes are putting pressure on what many leaders have relied on as a stable, margin accretive business. In this episode, host Abby Burns sits down with Advisory Board expert Chloe Bakst to break down what's actually happening in the infusion market — and why every health system leader should be paying closer attention. Together, they explore how new competitors are capturing leakage you may not even see, how payers and employers are steering patients away from hospital outpatient departments, and how upcoming 340B reforms and Medicare drug price negotiations could reshape the economics of infusion over the next three years. Chloe also shares the strategies forward thinking systems are using to protect their infusion business and prepare for rapidly emerging headwinds. We're here to help: Webinar | The top trends in today's infusion market Tool | Market Scenario Planner Ready-to-Use Resource | Policy Scenario Impact Calculator Expert Insight | The 3 trends reshaping the specialty drug pipeline today Podcast | 270: Service line snapshot: What every health leader needs to know Webinar | Join Optum Advisory experts at this upcoming webinar to learn how optimizing patient access unlocks the value of digital innovations and drives long-term sustainability. Expert Insight | How data-driven risk reduction protects patients and providers A transcript of this episode as well as more information and resources can be found on RadioAdvisory.advisory.com.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.Some of the biggest recent policy developments for 340B hospitals are when states enact legislation to protect access to 340B pricing through contract pharmacies. Olivia Little, 340B director at Johnson County Hospital in Tecumseh, Neb., was closely involved with a coalition of providers that was able to get such a bill passed through the state's legislature and signed into law by the governor. But she describes why getting the law enacted wasn't the end of the story.A Wide Range of ResponsesLittle says once her state's contract pharmacy protection law went into effect, she began receiving notices about 340B pricing being restored from some drug companies. But not all drugmakers restored previous pricing levels right away in Nebraska — some took months, and some have not yet done so despite the law going into effect nearly a year ago. The wide range of ways in which companies responded to the new law created difficult choices for hospitals between risking a potential compliance issue or leaving some 340B savings on the table. Having a Game PlanLittle says her advice to other health systems in states with new contract pharmacy protections would be to have a plan in place for what happens when the law goes into effect. Implementing these protections can raise questions about issue such as backdating, inventory, and retesting claims for 340B status. The complex tracking of multiple drugmaker policies in response to the Nebraska law resulted in her needing to closely document communications with drug companies and their vendors.The Need To Be PersistentLittle also stressed that getting pharmacy protections to pass through her state legislature and get to the governor's desk took years of effort, advocacy, and redrafting to ensure success. Between media appearances and advocating in the statehouse and on social media, Little says this success ultimately came down to the core message: 340B is good for patients, hospitals, and communities.Resources:HRSA Gives Short Window for Stakeholder Input on Reviving 340B Rebate Model

In this episode, Sam McCrimmon, J.D., Vice President of Development at Regional One Health, joins the podcast to discuss the growing role of philanthropy in safety net hospitals, from supporting patient access to funding major capital projects. He also shares insights on 340B, AI, federal funding shifts, and Regional One's vision for a new hospital and future academic medical center.

340B Insight wants to make our podcast the best it can be. To help us succeed, we'd like to hear your thoughts. Please take just a few minutes to complete our listener survey, and we will enter you in a drawing to win a $100 gift card! To participate, please go to 340bpodcast.org/survey.For the third year in a row, we consulted 340B Health's experts on our staff to answer our listeners' most pressing 340B questions. As 2026 gets underway, we answer your questions about the CMS drug acquisition cost survey, what states are doing on 340B this year, and more. Some of the topics we cover:CMS Drug Acquisition Cost Survey Not MandatoryEarlier this year, the Center for Medicare & Medicaid Services (CMS) launched a new survey focusing on hospitals' outpatient drug acquisition costs, which could lead to Medicare Part B payment cuts for 340B drugs. Some hospitals recently saw materials suggesting they are required to complete the survey. Amanda Nagrotsky, vice president of legal and policy for 340B Health, notes that a CMS rule states there are no penalties under the Medicare statute for hospitals that choose not to respond. 340B Health and other groups sent a joint letter asking for the language to be corrected, citing the confusion it has caused.State Legislatures Are Becoming Major Battlegrounds for 2026Just over one month into 2026, statehouses are already shaping up to be one of the biggest venues to debate various aspects of the 340B. Two broad categories of bills are emerging: legislation protecting access to 340B pricing — including protections for contract pharmacy arrangements — and state-level reporting mandates. 340B Health Senior Vice President of Government Relations Tom O'Donnell says the proposed reporting mandates mirror other states' recently enacted requirements, and he argues they can be misleading, burdensome, or modeled on frameworks promoted by large drug companies.Medicare Announces More Drug Price Caps for 2028Medicare is phasing in maximum fair pricing – or MFP – for high-spending drugs over several years. CMS recently announced the next group of 15 drugs that will be subject to these types of price caps in 2028, adding to the 2026 and 2027 drug lists. Starting in 2028, these price caps will apply to both Medicare Part D and Part B drugs, including those purchased through Medicare Advantage. 340B Health Senior Manager of Pharmacy Services Gilda Yeboah says this means hospitals will see reduced 340B savings on certain drugs as Medicare prices move closer to existing 340B ceiling prices. Yeboah says the issue is complex and evolving, and 340B Health is working to share concerns about MFP implementation with federal agencies.Resources340B Health and Allies Urge CMS Contractor To Correct Statement Suggesting Hospitals Must Respond to OPPS Drug Cost SurveyStates Introduce New 340B Legislation in 2026 SessionsMaine Federal Court Rejects Drug Company Challenge to State 340B Contract Pharmacy LawMedicare Expands List of Drugs Subject to Price Caps, Decreased 340B Savings Starting in 2028Manufacturer Notices to Covered EntitiesHRSA Releases 340B Purchase Data for 2024FY 2025 Manufacturer Audit Results

In this episode, Greg and Rob are joined again by healthcare attorney Emily Cook. They discuss a recent HRSA Information Collection Request (ICR) that describes some changes being made to the 340B enrollment, registration and recertification processes. They also discuss recent industry observations around hospital disproportionate share percentage calculations and impact on 340B Program eligibility. Going to 340B Coalition Winter Conference in San Diego? Come see the SpendMend team at booth #418!

In this episode, Rob and Greg are joined by guest Andy Ruskin, healthcare attorney and government payer expert from K&L Gates. They'll be discussing the 2026 CMS OPPS Final Rule, focusing on the provision related to the ODACS, or Outpatient Drug Acquisition Cost Survey. They'll review the statutory landscape surrounding the survey, recap past attempts by CMS to lower 340B hospital reimbursement, and discuss considerations for hospitals as they contemplate how to respond this time around. In the intro, the guys review updates to manufacturer 340B policies. Specifically, they discuss a new policy from one manufacturer that conditions 340B pricing access for in-house pharmacies on claim submission requirements. 

In this episode, Roya Tran, PharmD, MS, 340B ACE, Associate Chief Pharmacy Officer for Pharmacy Finance and Supply Chain at Duke Health, joins the podcast to discuss her experience with the 340B program and how it supports access to care. She shares perspectives on expanding the ambulatory pharmacy space, identifying growth opportunities, and improving access to pharmaceutical care through strategic finance and supply chain alignment.

The status quo is expensive, exhausting, and unsustainable—so we set out a practical playbook to do better in 2026. Nathan Kaufman shares ten no‑nonsense resolutions for health system leaders who want measurable outcomes, stronger teams, and smarter payer strategies without falling for vendor hype or wishful thinking.We get specific about capital discipline and why “mission” can't justify chronic losses that drain resources from services that actually improve patient care. We talk through what it takes to win the talent war by treating physicians as true partners, then dive into dyad leadership that cuts across supply chain, HR, and IT to remove friction and accelerate results. Culture becomes operational with real-time metrics, fast feedback loops, and leaders spending more time in the field and less time in meetings that signal low trust and unclear decisions.Payment strategy is front and center. We explain how to use 340B responsibly to close funding gaps, why some value-based schemes are a race to the bottom, and how to negotiate Medicare Advantage so contracts yield at least 100% of Medicare after accounting for administrative burden. Affordability demands that we take significant cost out by removing layers, standardizing clinical pathways, and focusing on core services rather than chasing panaceas like provider-owned health plans or sponsored “research” that flatters a product.If you're ready to lead with data, align teams, and make tough calls that protect patient access and quality, this conversation is your roadmap. Subscribe, share with a colleague who needs a dose of operational courage, and leave a review telling us which resolution you'll tackle first.Support the showEngage the conversation on Substack at The Common Bridge!